Sei Investments Co. Trims Holdings in Perrigo Company plc $PRGO

Sei Investments Co. lessened its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 43.3% in the first quarter, Holdings Channel.com reports. The fund owned 159,010 shares of the company’s stock after selling 121,359 shares during the period. Sei Investments Co.’s holdings in Perrigo were worth $1,708,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in PRGO. Amundi boosted its holdings in shares of Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after buying an additional 556 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Perrigo by 126.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after acquiring an additional 647,982 shares during the period. United Services Automobile Association purchased a new position in Perrigo during the 1st quarter valued at about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Perrigo by 6.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock worth $14,388,000 after acquiring an additional 32,151 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares during the period. Institutional investors own 95.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PRGO. Weiss Ratings upgraded Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Wall Street Zen upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Perrigo has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Price Performance

NYSE PRGO opened at $12.69 on Tuesday. The business’s fifty day moving average is $10.66 and its 200 day moving average is $11.49. Perrigo Company plc has a fifty-two week low of $9.23 and a fifty-two week high of $24.60. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.32 and a current ratio of 2.32. The company has a market capitalization of $1.76 billion, a PE ratio of -1.01, a price-to-earnings-growth ratio of 1.46 and a beta of 0.51.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.11. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The company’s revenue was down 3.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts predict that Perrigo Company plc will post 2.2 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be issued a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 9.1%. The ex-dividend date of this dividend is Friday, August 28th. Perrigo’s payout ratio is -9.27%.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.